1.  Cleeland CS, Keating KN, Cuffel B, Elbi C, Siegel JM, Gerlinger C, Symonds T, Sloan JA, Dueck AC, Bottomley A, Wang XS, Williams LA, Mendoza TR.            Developing a fit-for-purpose composite symptom  score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesothelioma.                  Sci.Rep. 2024 Jun 27;14(1):14839. doi: 10.1038/s41598-024-62307-5. PMID: 38937473; PMCID.   PMC11211485

       2.  Pilz MJ, Seyringer S, Al-Naesan I, King MT, Bottomley A, Norman R, Schlosser L, Hell T, Gamper EM. Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients-Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs. Pharmacoecon Open. 2024 May 2. doi: 10.1007/s41669-024-00484-9. Epub ahead of print. PMID: 38696019.

       3.  Pilz MJ, Seyringer S, Hallsson LR, Bottomley A, Jansen F, King MT, Norman R, Rutten MJ, Leeuw IMV, Siersema PD, Gamper EM. The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands. Eur J Health Econ. 2024 Mar 14. doi: 10.1007/s10198-024-01670-6. Epub ahead of print. PMID: 38483665.

       4.  Aiyegbusi, O.L., Cruz Rivera, S., Roydhouse, J.  Kamudoni, YA., Anderson N, Baldwin RM, Bhatnagar V, Black J, Bottomley A, Brundage M, Cella D, Collis P, Davies EH, Denniston AK, Gardner A, Gnanasakthy A, Golub RM, Hughes SE, Jeyes F, Kern S, King-Kallimanis BL, Martin A, McMullan K, Mercieca-Bebber R, Monteiro J, Peipert JD, Quijano-Campos JC, Quinten C, Regnault A, Sasseville M, Snyder C, Stover AM, Verdi R, Wilson R &. Calvert MJ. Recommendations to address respondent burden associated with patient-reported outcome assessment. Nat Med 30, 650–659, 2024. https://doi.org/10.1038/s41591-024-02827-9

       5.  Reijneveld JC, Machingura A, Coens C, Taphoorn MJB, Taal W, Clement PM, Idbaih A, de Vos FYF, Klein M, Wick W, Mulholland PJ, Lewis J, Golfinopoulos V, Ghislain I, Bottomley A, van den Bent MJ; EORTC Brain Tumor Group. Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091). Eur J Cancer. 2023 Jun 19;190:112946. doi: 10.1016/j.ejca.2023.112946. PMID: 37453240.

       6.  Caramanna I, Reijneveld JC, van de Ven PM, van den Bent M, Idbaih A, Wick W, Taphoorn MJB, Dirven L, Bottomley A, Klein M; EORTC Quality of Life Group and EORTC Brain Tumor Group. Association between objective neurocognitive functioning and neurocognitive complaints in recurrent high-grade glioma: Longitudinal evidence of cognitive awareness from EORTC brain tumour trials Eur J Cancer. 2023 Jun;186:38-51. doi: 10.1016/j.ejca.2023.02.029.

       7.  Pe M, Alanya A, Falk RS, Amdal CD, Bjordal K, Chang J, Cislo P, Coens C, Dirven L, Speck RM, Fitzgerald K, Galinsky J, Giesinger JM, Holzner B, Le Cessie S, O’Connor D, Oliver K, Pawar V, Quinten C, Schlichting M, Ren J, Roychoudhury S, Taphoorn MJB, Velikova G, Wintner LM, Griebsch I, Bottomley A; SISAQOL-IMI Consortium. Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures. Lancet Oncol. 2023 Jun;24(6):e270-e283. doi: 10.1016/S1470-2045(23)00157-2.PMID: 37269858

       8.  Musoro JZ, Coens C, Sprangers MAG, Brandberg Y, Groenvold M, Flechtner HH, Cocks K, Velikova G, Dirven L, Greimel E, Singer S, Pogoda K, Gamper EM, Sodergren SC, Eggermont A, Koller M, Reijneveld JC, Taphoorn MJB, King MT, Bottomley A; EORTC Melanoma, Breast, Head and Neck, Genito-urinary, Gynecological, Gastro-intestinal, Brain, Lung and Quality of Life Groups. Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types. Eur J Cancer. 2023 Jul;188:171-182. doi: 10.1016/j.ejca.2023.04.027.

       9.  Piccinin C, Basch E, Bhatnagar V, Calvert M, Campbell A, Cella D, Cleeland CS, Coens C, Darlington AS, Dueck AC, Groenvold M, Herold R, King-Kallimanis BL, Kluetz PG, Kuliś D, O’Connor D, Oliver K, Pe M, Reeve BB, Reijneveld JC, Wang XS, Bottomley A. Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group. Lancet Oncol. 2023 Feb;24(2):e86-e95. doi: 10.1016/S1470-2045(22)00654-4.

    10.  Pilz MJ, Nolte S, Liegl G, King M, Norman R, McTaggart-Cowan H, Bottomley A, Rose M, Kemmler G, Holzner B, Gamper EM; EORTC Quality of Life Group. The EORTC QLU-C10D – development and investigation of general population utility norms for Canada, France, Germany, Italy, Poland and the U.K; Value Health. 2022 Dec 23:S1098-3015(22)04783-0. doi: 10.1016/j.jval.2022.12.009.

    11.  Oosting SF, Barriuso J, Bottomley A, Galotti M, Gyawali B, Kiesewetter B, Latino NJ, Martinelli F, Pe M, Pentheroudakis G, Roitberg F, Vachon H, de Vries EGE, Piccart M, Cherny NI; ESMO-MCBS Working Group and Extended Working Group. Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit; Ann Oncol. 2022 Dec 19:S0923-7534(22)04772-X. doi: 10.1016/j.annonc.2022.12.004.

    12.  Cocks K, Wells JR, Johnson C, Schmidt H, Koller M, Oerlemans S, Velikova G, Pinto M, Tomaszewski KA, Aaronson NK, Exall E, Finbow C, Fitzsimmons D, Grant L, Groenvold M, Tolley C, Wheelwright S, Bottomley A; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life; Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer; Eur J Cancer. 2023 Jan;178:128-138. doi: 10.1016/j.ejca.2022.10.026. Epub 2022 Nov 1.

    13.  Amdal CD, Falk RS, Singer S, Pe M, Piccinin C, Bottomley A, Appiah LT, Arraras JI, Bayer O, Buanes EA, Darlington AS, Arbanas GD, Hofsø K, Holzner B, Sahlstrand-Johnson P, Kuliś D, Parmar G, Rmeileh NMEA, Schranz M, Sodergren S, Bjordal K. A multicenter international prospective study of the validity and reliability of a COVID-19-specific health-related quality of life questionnaire; Qual Life Res, 2022 Oct 23. doi: 10.1007/s11136-022-03272-2.

    14.  Caramanna I, Klein M, van den Bent M, Idbaih A, Wick W, Taphoorn MJB, Dirven L, Bottomley A, Reijneveld JC; EORTC Quality of Life Group and EORTC Brain Tumor Group. Neurocognitive impairment and patient-proxy agreement on health-related quality of life evaluations in recurrent high-grade glioma patients; Qual Life Res. 2022 Aug 18.doi: 10.1007/s11136-022-03197-w.

    15.  Gilbert A, Piccinin C, Velikova G, Groenvold M, Kuliś D, Blazeby JM, Bottomley A. Linking the European Organisation for Research and Treatment of Cancer Item Library to the Common Terminology Criteria for Adverse Events; J Clin Oncol. 2022 Aug 16;JCO2102017. doi: 10.1200/JCO.21.02017

    16.  Koller M, Musoro JZ, Tomaszewski K, Coens C, King MT, Sprangers MAG, Groenvold M, Cocks K, Velikova G, Flechtner HH, Bottomley A. Corrigendum to “Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trials” [Lung Cancer 167C (2022) 65-72]; Lung Cancer. 2022 Sep;171:126. doi: 10.1016/j.lungcan.2022.05.006. Epub 2022 May 20.

    17.  Cruz Rivera S, Aiyegbusi OL, Ives J, Draper H, Mercieca-Bebber R, Ells C, Hunn A, Scott JA, Fernandez CV, Dickens AP, Anderson N, Bhatnagar V, Bottomley A, Campbell L, Collett C, Collis P, Craig K, Davies H, Golub R, Gosden L, Gnanasakthy A, Haf Davies E, von Hildebrand M, Lord JM, Mahendraratnam N, Miyaji T, Morel T, Monteiro J, Zwisler AO, Peipert JD, Roydhouse J, Stover AM, Wilson R, Yap C, Calvert MJ. Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical Research: The PRO Ethics Guidelines, JAMA. 2022 May 17;327(19):1910-1919. doi: 10.1001/jama.2022.6421.

    18.  Machingura A, Taye M, Musoro J, Ringash J, Pe M, Coens C, Martinelli F, Tu D, Basch E, Brandberg Y, Grønvold M, Eggermont A, Cardoso F, Van Meerbeeck J, van der Graaf WTA, Taphoorn M, Reijneveld JC, Soffietti R, Sloan J, Velikova G, Flechtner H, Bottomley A; EORTC Quality of Life Group, Brain tumour, Breast Cancer, Melanoma Group, Lung Cancer, Soft Tissue and Bone Sarcoma, Lymphoma, Gastrointestinal Tract Cancer, Head and Neck Cancer, Genito-Urinary Cancers, and Gynecological Cancer Groups. Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study. Eur J Cancer. 2022 May 12;170:1-9. doi: 10.1016/j.ejca.2022.03.039.

    19.  Koller M, Musoro JZ, Tomaszewski K, Coens C, King MT, Sprangers MAG, Groenvold M, Cocks K, Velikova G, Flechtner HH, Bottomley A. Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trials; Lung Cancer. 2022 May;167:65-72. doi: 10.1016/j.lungcan.2022.03.018. Epub 2022 Mar 29.

    20.  Coomans M, Dirven L, Aaronson N, Baumert BG, van den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB; EORTC Quality of Life Group and the EORTC Brain Tumor Group. Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period; Neuro Oncol. 2022 Apr 11:noac097. doi: 10.1093/neuonc/noac097.

    21.  Amdal CD, Taylor K, Kuliś D, Falk RS, Bottomley A, Arraras JI, Barte JH, Darlington AS, Hofsø K, Holzner B, Jørgensen NMH, Mariano MP, Pe M, Piccinin C, Riccetti N, Schranz M, Wheelwright S, Bjordal K. Health-related quality of life in patients with COVID-19; international development of a patient-reported outcome measure, J Patient Rep Outcomes. 2022 Mar 26;6(1):26. doi: 10.1186/s41687-022-00434-1.

    22.  Dal Lago L, Uwimana AL, Coens C, Vuylsteke P, Curigliano G, Brouwers B, Jagiello-Gruszfeld A, Altintas S, Tryfonidis K, Poncet C, Bottomley A, Sousa B, Brain E, Wildiers H; Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial; J Geriatr Oncol. 2022 Jan 28:S1879-4068(22)00010-8. doi: 10.1016/j.jgo.2022.01.009.

    23.  Snyder C, Crossnohere N, King M, Reeve BB, Bottomley A, Calvert M, Thorner E, Wu AW, Brundage M; The PROTEUS-Trials Consortium: Optimizing the use of patient-reported outcomes in clinical trials. PROTEUS-Trials Consortium. Clin Trials. 2022 Jan 31:17407745221077691. doi: 10.1177/17407745221077691.

    24.  Dal Lago L, Uwimana AL, Coens C, Vuylsteke P, Curigliano G, Brouwers B, Jagiello-Gruszfeld A, Altintas S, Tryfonidis K, Poncet C, Bottomley A, Sousa B, Brain E, Wildiers H. Share; Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial. J Geriatr Oncol. 2022 Jan 28:S1879-4068(22)00010-8. doi: 10.1016/j.jgo.2022.01.009.

    25.  Sztankay M, Wintner LM, Roggendorf S, Nordhausen T, Dirven L, Taphoorn MJB, Leeuw IMV, Velikova G, Bottomley A, Kulis D, Kachel T, Schmidt H; EORTC Quality of Life Group. Developing an e-learning course on the use of PRO measures in oncological practice: health care professionals’ preferences for learning content and methods Support, Care Cancer. 2021 Nov 19. doi: 10.1007/s00520-021-06676-x.

    26.  Koller M, Müller K, Nolte S, Schmidt H, Harvey C, Mölle U, Boehm A, Engeler D, Metzger J, Sztankay M, Holzner B, Groenvold M, Kuliś D, Bottomley A; EORTC Quality of Life Group. Investigating the response scale of the EORTC QLQ-C30 in German cancer patients and a population survey, Health Qual Life Outcomes. 2021 Oct 9;19(1):235. doi: 10.1186/s12955-021-01866-x.

    27.  Gamper EM, Musoro JZ, Coens C, Stelmes JJ, Falato C, Groenvold M, Velikova G, Cocks K, Flechtner HH, King MT, Bottomley A; EORTC Genito-Urinary Tract Cancer Group and Quality of Life Groups. Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials, BMC Cancer. 2021 Oct 7;21(1):1083. doi: 10.1186/s12885-021-08609-7.

    28.  Piccinin C, Pe M, Kuliś D, Shaw JW, Wheelwright SJ, Bottomley A. Equivalence testing of a newly developed interviewer-led telephone script for the EORTC QLQ-C30, Qual Life Res. 2021 Jul 20. doi: 10.1007/s11136-021-02955-6.

    29.  Calvert M, King M, Mercieca-Bebber R, Aiyegbusi O, Kyte D, Slade A, Chan AW, Basch E, Bell J, Bennett A, Bhatnagar V, Blazeby J, Bottomley A, Brown J, Brundage M, Campbell L, Cappelleri JC, Draper H, Dueck AC, Ells C, Frank L, Golub RM, Griebsch I, Haywood K, Hunn A, King-Kallimanis B, Martin L, Mitchell S, Morel T, Nelson L, Norquist J, O’Connor D, Palmer M, Patrick D, Price G, Regnault A, Retzer A, Revicki D, Scott J, Stephens R, Turner G, Valakas A, Velikova G, von Hildebrand M, Walker A, Wenzel L. SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials, BMJ Open. 2021 Jun 30;11(6):e045105. doi: 10.1136/bmjopen-2020-045105.

    30.  Amdal CD, Pe M, Falk RS, Piccinin C, Bottomley A, Arraras JI, Darlington AS, Hofsø K, Holzner B, Jørgensen NMH, Kulis D, Rimehaug SA, Singer S, Taylor K, Wheelwright S, Bjordal K. Health-related quality of life issues, including symptoms, in patients with active COVID-19 or post COVID-19; a systematic literature review, Qual Life Res. 2021 Jun 19:1-15. doi: 10.1007/s11136-021-02908-z.

    31.  Piccinin C, Bottomley A, Velikova G, Groenvold M, Kuliś D, Blazeby JM, Gilbert A, Coverage of symptomatic toxicities from the common terminology criteria for adverse events (CTCAE) framework within the european organization for research and treatment of cancer (EORTC) item library. Journal of Clinical Oncology 39, no. 15_suppl. 2021 May 28, doi: 10.1200/JCO.2021.39.15_suppl.e24117

    32.  Lehmann J, Holzner B, Giesinger JM, Bottomley A, Ansari S, von Butler L, Kemmler G. Functional health and symptoms in Spain before and during the COVID-19 pandemic, BMC Public Health. 2021 May 1;21(1):837. doi: 10.1186/s12889-021-10899-2.

    33.  Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Puig S, Ascierto PA, Larkin J, Lorigan PC, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C, Eggermont AMM; EORTC Melanoma Group. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial Lancet Oncol. 2021 May;22(5):655-664. doi: 10.1016/S1470-2045(21)00081-4. Epub 2021 Apr 12.

    34.  Dirven L, Musoro JZ, Coens C, Reijneveld JC, Taphoorn MJB, Boele FW, Groenvold M, van den Bent MJ, Stupp R, Velikova G, Cocks K, Sprangers MAG, King MT, Flechtner HH, Bottomley A. Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients, Neuro Oncol. 2021 Feb 18:noab037. doi: 10.1093/neuonc/noab037.

    35.  Vachon H, Mierzynska J, Taye M, Pe M, Coens C, Martinelli F, Fortpied C, Flechtner HH, Vestmoe Maraldo M, Hutchings M, Meijnders P, Aleman B, Lugtenburg P, Spina M, André M, Hertzberg M, Briones J, Bottomley A, EORTC Quality of Life Group, Lymphoma Group, Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors, Eur J Haematol. 2021 May;106(5):697-707. doi: 10.1111/ejh.13601.

    36.  Sodergren SC, Wheelwright SJ, Fitzsimmons D, Efficace F, Sprangers M, Fayers P, Harle A, Schmidt H, Bottomley A, Darlington AS, Benson C, Bredart A, Hentschel L, Arraras JI, Ioannidis G, Leahy M, Lugowska I, Nicolatou-Galitis O, Petranovic D, Rohde GE, Vassiliou V, Johnson CD; EORTC Quality of Life Group. Developing symptom lists for people with cancer treated with targeted therapies, Target Oncol. 2021 Jan;16(1):95-107. doi: 10.1007/s11523-020-00769-z.

    37.  Coomans MB, Dirven L, Aaronson NK, Baumert BG, van den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Sloan JA, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB, Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modelling, Neurooncol Adv. 2020 Oct 29;2(1):vdaa147. doi: 10.1093/noajnl/vdaa147

    38.  Caramanna I, Bottomley A, Drijver AJ, Twisk J, van den Bent M, Idbaih A, Wick W, Pe M, Klein M, Reijneveld JC, EORTC Quality of Life Group and Brain Tumour Group. Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials, Eur J Cancer. 2020 Dec 18;144:162-168. doi: 10.1016/j.ejca.2020.10.040.

    39.  Musoro JM, Coens C, Singer S, Tribius S, Oosting SF, Groenvold M, Simon C, Machiels JP, Grégoire V, Velikova G, Cocks K, Sprangers MAG, King MT, Bottomley A, EORTC Head and Neck and Quality of Life Groups; Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer; Head Neck. 2020 Nov;42(11):3141-3152.doi: 10.1002/hed.26363. Epub 2020 Jul 6.

    40.  Wintner L, Giesinger JM, Sztankay M, Bottomley A, Holzner B on behalf of the EORTC Quality of Life Group; Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial. Trials. 2020 Oct 13;21(1):849. doi: 10.1186/s13063-020-04745-w.

    41.  Terada M, Nakamura K, Martinelli F, Pe M, Mizusawa J, Eba J, Fukuda H, Kiyota N, Gatellier L, Majima Y, Velikova G, Bottomley A; Results from a 1-day workshop on the assessment of quality of life in cancer patients: a joint initiative of the Japan Clinical Oncology Group and the European Organisation for Research and Treatment of Cancer; Jpn J Clin Oncol. 2020 Oct 22;50(11):1333-1341. doi: 10.1093/jjco/hyaa119.

    42.  Fiero MH, Pe M, Weinstock C, King-Kallimanis BL, Komo S, Klepin HD, Gray SW, Bottomley A, Kluetz P, Sridhara R; Demystifying the estimand framework: a case study using patient-reported outcomes in oncology; The Lancet Oncology, Lancet Oncol. 2020 Oct;21(10):e488-e494. doi: 10.1016/S1470-2045(20)30319-3.

    43.  Bjelic-Radisic V, Cardoso F, Cameron D, Brain E, Kuljanic K, da Costa RA, Conroy T, Inwald EC, Serpentini S, Pinto M, Weis J, Morag O, Lindviksmoen Astrup G, Tomaszweksi K, Pogoda K, Sinai P, Sprangers M, Aaronson N, Velikova G, Greimel E, Arraras J, Bottomley A, EORTC Quality of Life Group and Breast Cancer Group; An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45; Ann Oncol 2020 Feb;31(2):283-288. doi: 10.1016/j.annonc.2019.10.027. Epub 2019 Dec 18.

    44.  Koch M, Jensen Hjermstad M, Tomaszewski K, Tomaszewska I, Hornslien K, Harle A, Arraras J, Morag O, Pompili C, Ioannidis G, Navarra C, Chie W, Johnson C, Bohrer T, Janssens A, Kulis D, Bottomley A, Schulz C, Zeman F, Koller M; Gender effects on quality of life and symptom burden in patients with lung cancer: results from a prospective, cross-cultural, multi-center study; J Thorac Dis. 2020 Aug; 12(8): 4253–4261. doi: 10.21037/jtd-20-1054

    45.  Coomans M, Taphoorn M, Aaronson N, Baumert B, van den Bent M, Bottomley A, Brandes A, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld J, Dirven L, EORTC Quality of Life Group and the EORTC Brain Tumor Group. Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients. Neurooncol Pract. 2020 Dec; 7(6): 668–675. doi: 10.1093/nop/npaa033

    46.  Koller M, Shamieh O, Hjermstad MJ, Hornslien K, Young T, Chalk T, Ioannidis G, Harle A, Johnson CD, Tomaszewski KA, Serpentini S, Pinto M, van der Weijst L, Janssens A, Morag O, Chie WC, Arraras JI, Pompili C, Jungraithmayr W, Hechtner M, Katsochi D, Müller K, Gräfenstein L, Schulz C, Bottomley A; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group; EORTC Lung Cancer Group; European Society of Thoracic Surgeons. Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study. Lancet Oncol. 2020 May;21(5):723-732.doi: 10.1016/S1470-2045(20)30093-0. Epub 2020 Mar 23.

    47.  Coens C, Pe M, Dueck AC, Sloan J, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Dorme L, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro J, O’Connor D, Oliver K, Piault-Louis E, Piccart M, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Taphoorn M, Velikova G, Bottomley A. International Standards for the Analysis of Quality of Life and Patient Reported Outcomes Endpoints in Cancer Randomised Controlled Trials; Recommendations based on critical reviews of the literature and international multi-expert, multi-stakeholder collaborative process. Lancet Oncol. 2020 Feb;21(2):e83-e96.doi: 10.1016/S1470-2045(19)30790-9.

    48.  Mierzynska J, Taye M, Pe M, Coens C, Martinelli F, Pogoda K, Velikova G, Bjelic-Radisic V, Cardoso F, Brain E, Ignatiadis M, Piccart M, Van Tienhoven G, Mansel R, Wildiers H, Bottomley A; EORTC and EORTC Breast Cancer Group. Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. Eur J Cancer. 2020 Jan;125:69-82. doi: 10.1016/j.ejca.2019.10.031.

    49.  Coomans MB, Dirven L, Aaronson NK, Baumert BG, Van Den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB. Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status? Neuro Oncol. 2019 Nov 4;21(11):1447-1457. doi: 10.1093/neuonc/noz118.

    50.  Mierzynska J, Piccinin C, Pe M, Martinelli F, Gotay C,  Coens C, Mauer M, Eggermont, Groenvold M, Bjordal K, Reijneveld J, Velikova G, Bottomley A. An evaluation of the prognostic value of patient-reported outcomes from international cancer randomized clinical trials. Lancet Oncol. 2019 Dec;20(12):e685-e698.doi: 10.1016/S1470-2045(19)30656-4.

    51.  Musoro JZ, Coens, C, Fetini, F, Katarzyna P, Cardoso F, Russell NS,  King MT, Cocks K, Sprangers MA, Groenvold MVelikova G, Flechtner HH, Bottomley A on behalf of the EORTC Breast and Quality of Life Groups G, Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer, JNCI Cancer Spectr. 2019 Jun 4;3(3):pkz037.doi: 10.1093/jncics/pkz037. eCollection 2019 Sep

    52.  Bottomley A, Reijneveld JC, Koller M, Flechtner H, Tomaszewski KA, Greimel E; 5th EORTC Quality of Life in Cancer Clinical Trials Conference Faculty. Current state of quality of life and patient-reported outcomes research. Eur J Cancer. 2019 Sep 24;121:55-63. doi: 10.1016/j.ejca.2019.08.016.

    53.  Weis J, Wirtz MA, Tomaszewski KA, Hammerlid E, Arraras JI, Conroy T, Lanceley A, Schmidt H, Singer S, Pinto M, Alm El-Din M, Compter I, Holzner B, Hofmeister D, Chie WC, Harle A, Flechtner HH, Bottomley A; EORTC Quality of Life Group. Sensitivity to change of the EORTC quality of life module measuring cancer related fatigue (EORTC QlQ-Fa12): results from the international psychometric validation. Psychooncology. 2019 Aug;28(8):1753-1761. doi: 10.1002/pon.5151. Epub 2019 Jul 9.

    54.  Coomans M, Dirven L, K Aaronson N, Baumert BG, van den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB; EORTC Quality of Life Group and the EORTC Brain Tumor Group. The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. Eur J Cancer. 2019 Jul;116:190-198. doi: 10.1016/j.ejca.2019.05.012. Epub 2019 Jun 13.

    55.  Musoro JZ, Bottomley A, Coens C, Eggermont AM, King MT, Cocks K, Sprangers MA, Groenvold M, Velikova G, Flechtner HH, Brandberg Y; EORTC Melanoma Group and EORTC Quality of Life Group. Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma. Eur J Cancer. 2018 Nov;104:169-181. doi: 10.1016/j.ejca.2018.09.005. Epub 2018 Oct 22.

    56.  Pe M, Dorme L, Coens C, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dirven L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Sloan J, Velikova G, Bottomley A; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium (SISAQOL). Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. Lancet Oncol. 2018 Sep;19(9):e459-e469. doi: 10.1016/S1470-2045(18) 30418-2.

    57.  Koch M, Jensen Hjermstad M, Tomaszewski K, Tomaszewska I, Hornslien K, Harle A, Arraras J, Morag O, Pompili C, Ioannidis G, Georgu M, Navarra C, Chie W, Johnson C, Himpel A, Schulz C, Bohrer T, Janssens A, Kulis D, Bottomley A, Koller M. Gender Aspekte in der Lebensqualität von Lungenkarzinom Patienten. Pneumologie 2018; 72(S 01): S37, P373. doi: 10.1055/s-0037-1619214

    58.  Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JF, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Moinpour CM, Musoro JZ, O’Connor D, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Sridhara R, Taphoorn MJB, Velikova G, Coens C; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) Consortium. Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials. Clin Trials. 2018 Aug 24:1740774518795637. doi: 10.1177/1740774518795637.

    59.  Ediebah DE, Quinten C, Coens C, Ringash J, Dancey J, Zikos E, Gotay C, Brundage M, Tu D, Flechtner HH, Greimel E, Reeve BB, Taphoorn M, Reijneveld J, Dirven L, Bottomley A. Canadian Cancer Trials Group and the European Organization for Research and Treatment of Cancer. Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials. Cancer. 2018 Aug;124(16):3409-3416. doi: 10.1002/cncr.31556. Epub 2018 Jun 15.

    60.  Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT; the SPIRIT-PRO Group, Hunn A, Bottomley A, Regnault A, Chan AW, Ells C, O’Connor D, Revicki D, Patrick D, Altman D, Basch E, Velikova G, Price G, Draper H, Blazeby J, Scott J, Coast J, Norquist J, Brown J, Haywood K, Johnson LL, Campbell L, Frank L, von Hildebrand M, Brundage M, Palmer M, Kluetz P, Stephens R, Golub RM, Mitchell S, Groves T. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018 Feb 6;319(5):483-494. doi: 10.1001/jama.2017.21903.

    61.  Musoro ZJ, Hamel JF, Ediebah DE, Cocks K, King MT, Groenvold M, Sprangers MAG, Brandberg Y, Velikova G, Maringwa J, Flechtner HH, Bottomley A, Coens C, EORTC Quality of Life Group. Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol. BMJ Open. 2018 Jan 10;8(1):e019117. doi: 10.1136/bmjopen-2017-019117.

    62.  Quinten C, Kenis C, Hamaker M, Coolbrandt A, Brouwers B, Dal Lago L, Neven P, Vuylsteke P, Debrock G, Van Den Bulck H, Smeets A, Schöffski P, Bottomley A, Wedding U, Wildiers H. The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged ≥70 with early stage invasive breast cancer. J Geriatr Oncol. 2017 Nov 19. pii: S1879-4068(17)30213-8. doi: 10.1016/j.jgo.2017.10.001. [Epub ahead of print]

    63.  Kuliś D, Whittaker C, Greimel E, Bottomley A, Koller M; EORTC Quality of Life Group. Reviewing back translation reports of questionnaires: the EORTC conceptual framework and experience. Expert Rev Pharmacoecon Outcomes Res. 2017 Oct 5:1-8. doi: 10.1080/14737167.2017.1384316. [Epub ahead of print] PMID: 28974101

    64.  Marta GN, Moraes FY, Leite ETT, Chow E, Cella D, Bottomley A. A critical evaluation of quality of life in clinical trials of breast cancer patients treated with radiation therapy. Ann Palliat Med. 2017 Oct 24. pii: apm.2017.09.06. doi: 10.21037/apm.2017.09.06. [Epub ahead of print]

    65.  Koller M, Hjermstad MJ, Tomaszewski KA, Tomaszewska IM, Hornslien K, Harle A, Arraras JI, Morag O, Pompili C, Ioannidis G, Georgiou M, Navarra C, Chie WC, Johnson CD, Himpel A, Schulz C, Bohrer T, Janssens A, Kulis D, Bottomley A; EORTC Quality of Life Group, EORTC Lung Cancer Group, and European Society of Thoracic Surgeons. An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients. Ann Oncol. 2017 Nov 1;28(11):2874-2881. doi: 10.1093/annonc/mdx453.

    66.  Hamel JF, Saulnier P, Pe M, Zikos E, Musoro J, Coens C, Bottomley A. A systematic review of the quality of statistical methods employed for analysing quality of life data in cancer randomised controlled trials. Eur J Cancer. 2017 Jul 21;83:166-176. doi: 10.1016/j.ejca.2017.06.025. [Epub ahead of print]

    67.  Paradowska D, Bereza K, Sanna B, Kucharska E, Tomaszewska IM, Dudkiewicz Z, Skotnicki P, Bottomley A, Tomaszewski KA. A prospective study to validate the Polish language version of the European Organisation for Research and Treatment of Cancer (EORTC) Colorectal Liver Metastases (QLQ-LMC21) module. Eur J Oncol Nurs. 2017 May 31. doi: 10.1016/j.ejon.2017.05.006. [Epub ahead of print]

    68.  Sanna B, Bereza K, Paradowska D, Kucharska E, Tomaszewska IM, Dudkiewicz Z, Golec J, Bottomley A, Tomaszewski KA. A large scale prospective clinical and psychometric validation of the EORTC colorectal (QLQ-CR29) module in Polish patients with colorectal cancer. Eur J Cancer Care (Engl). 2017 May 11. doi: 10.1111/ecc.12713. [Epub ahead of print]

    69.  Weis J,Tomaszewski K, Hammerlid E, Arraras J.I., Conroy T, Lanceley A, Schmidt H, Wirtz M, Singer S, Pinto M, Alm El-Din MA, Compter I, Holzner B, Hofmeister D, Chie WC, Czeladzki M, Harle A, Jones L, Ritter S, Flechtner H-H, Bottomley A; International Psychometric Validation of an EORTC Quality of Life Module Measuring Cancer Related Fatigue (EORTC QLQ-FA12). J Natl Cancer Inst. 2017 Feb 7. 109(5). doi: 10.1093/jnci/djw273

    70.  Bjordal K, Bottomley A. Making Advances in Quality of Life Studies in Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):659-661. doi: 10.1016/j.ijrobp.2016.11.051. PMID: 28244403

    71.  Coens C, Suciu S, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok J D, Schmidt H, Hamid O, Robert C, Ascierto P A, Richards J M, Lebbe C, Ferraresi V, Smylie M, Weber J, Maio M, Bottomley A, Kotapati S, Pril V, Testori A, Eggermont A M M; Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of amultinational, randomised, double-blind, phase 3 trial. Lancet Oncol. 2017 Feb 2;18:393–403.  doi :10.1016/S1470-2045(17)30015-3

    72.  Eaton A, Karanicolas P, Johnson C, Bottomley A, Allen PJ, Gonen M. Psychometric Validation of the EORTC QLQ-PAN26 Pancreatic Cancer Module for Assessing Health Related Quality of Life after Pancreatic Resection. Journal of the Pancreas. 2017 Jan 25;18(1):19-25.

    73.  Vinik A, Bottomley A, Korytowsky B, Bang YJ, Raoul JL, Valle JW, Metrakos P, Hörsch D, Mundayat R, Reisman A, Wang Z, Chao RC, Raymond E. Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial. Target Oncol. 2016 Dec;11(6):815-524. doi:10.1007/s11523-016-0462-5

    74.  Hamel JF, Pe M, Coens C, Martinelli F, Eggermont AM, Brandberg Y, Bottomley A. A systematic review examining factors influencing health related quality of life among melanoma cancer survivors. Eur J Cancer. 2016 Nov 10;69:189-198. doi: 10.1016/j.ejca.2016.10.008. [Epub ahead of print] Review

    75.  Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JF, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Moinpour CM, Musoro J, O’Connor D, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Taphoorn MJ, Velikova G, Coens C; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium. Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncol. 2016 Oct 18;17(11):510-514. pii: S1470-2045(16)30510-1. doi: 10.1016/S1470-2045(16)30510-1. [Epub ahead of print]

    76.  Ediebah DE, Reijneveld JC, Taphoorn MJ, Coens C, Zikos E, Aaronson NK, Heimans JJ, Bottomley A, Klein M; EORTC Quality of Life Department and Patient Reported Outcome and Behavioral Evidence (PROBE). Impact of neurocognitive deficits on patient-proxy agreement regarding health-related quality of life in low-grade glioma patients. Qual Life Res. 2016 Oct 15;26(4):869. doi:10.1007/s11136-016-1426-z [Epub ahead of print]

    77.  Wintner LM, Sztankay M, Aaronson N, Bottomley A, Giesinger JM, Groenvold M, Petersen MA, van de Poll-Franse L, Velikova G, Verdonck-de Leeuw I, Holzner B; EORTC Quality of Life Group. The use of EORTC measures in daily clinical practice-A synopsis of a newly developed manual. Eur J Cancer. 2016 Oct 6;68:73-81. doi: 10.1016/j.ejca.2016.08.024. [Epub ahead of print]

    78.  Reijneveld JC, Taphoorn MJ, Coens C, Bromberg JE, Mason WP, Hoang-Xuan K, Ryan G, Hassel MB, Enting RH, Brandes AA, Wick A, Chinot O, Reni M, Kantor G, Thiessen B, Klein M, Verger E, Borchers C, Hau P, Back M, Smits A, Golfinopoulos V, Gorlia T, Bottomley A, Stupp R, Baumert BG. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016 Sep;2617(11):1533-1542. pii: S1470-2045(16)30305-9. doi: 10.1016/S1470-2045(16)30305-9

    79.  Ghislain I, Zikos E, Coens C, Quinten C, Balta V, Tryfonidis K, Piccart M, Zardavas D, Nagele E, Bjelic-Radisic V, Cardoso F, Sprangers MA, Velikova G, Bottomley A; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group; Breast Cancer Group; EORTC Headquarters. Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials. Lancet Oncol. 2016 Jul;17(7):e294-304. doi: 10.1016/S1470-2045(16)30099-7. Review

    80.  Miki-Rosário N, Garcia Filho RJ, Garcia JG, Dini GM, Bottomley A, Chow E, Sabino Neto M. Translation into Portuguese, cross-cultural adaptation and validation of “The European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire-Bone Metastases-22”. Ann Palliat Med. 2016 Jun 17. pii: apm.2016.06.02. doi: 10.21037/apm.2016.06.02.

    81.  Ganesh V, Agarwal A, Popovic M, Cella D, McDonald R, Vuong S, Lam H, Rowbottom L, Chan S, Barakat T, DeAngelis C, Borean M, Chow E, Bottomley A. Comparison of the FACT-C, EORTC QLQ-CR38, and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature review. Support Care Cancer. 2016 May 18. [Epub ahead of print]

    82.  King S, Exley J, Parks S, Ball S, Bienkowska-Gibbs T, MacLure C, Harte E, Stewart K, Larkin J, Bottomley A, Marjanovic S. The use and impact of quality of life assessment tools in clinical care settings for cancer patients, with a particular emphasis on brain cancer: insights from a systematic review and stakeholder consultations. Qual Life Res. 2016 Apr 2. [Epub ahead of print]

    83.  Woo A, Fu T, Popovic M, Chow E, Cella D, Wong CS, Lam H, Pulenzas N, Lechner B, Vuong S, Ganesh V, Bottomley A. Comparison of the EORTC STO-22 and the FACT-Ga quality of life questionnaires for patients with gastric cancer. Ann Palliat Med. 2015 Dec 16;5(1):13-21. doi: 10.3978/j.issn.2224-5820.2016.01.02

    84.  Zikos E, Coens C, Bottomley, A. Health related Quality of Life in EORTC clinical trials: An empathsis on quality. Belg J Med Oncol 2015; 9 (1):11-15

    85.  Zikos E, Coens C, Quinten C, Ediebah DE, Martinelli F, Ghislain I, King MT, Gotay C, Ringash J, Velikova G, Reeve BB, Greimel E, Cleeland CS, Flechtner H, Taphoorn MJ, Weis J, Schmucker-von Koch J, Sprangers MA, Bottomley A; The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative. J Natl Cancer Inst. 2015 Dec 28;108(5). doi: 10.1093/jnci/djv391 Print 2016 May

    86.  Sodergren SC, Copson E, White A, Efficace F, Sprangers M, Fitzsimmons D, Bottomley A, Johnson CD. Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group. Target Oncol. 2015 Dec 18. PMID: 26677846

    87.  Quinten C, Coens C, Ghislain I, Zikos E, Sprangers MA, Ringash J, Martinelli F, Ediebah DE, Maringwa J, Reeve BB, Greimel E, King MT, Bjordal K, Flechtner HH, Schmucker-Von Koch J, Taphoorn MJ, Weis J, Wildiers H, Velikova G, Bottomley A; PROBE; EORTC Clinical Groups. The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. Eur J Cancer. 2015 Dec;51(18):2808-19. doi: 10.1016/j.ejca.2015.08.027. Epub 2015 Nov 19. PMID: 26602015

    88.  Koller M, Warncke S, Hjermstad MJ, Arraras J, Pompili C, Harle A, Johnson CD, Chie WC, Schulz C, Zeman F, van Meerbeeck JP, Kuliś D, Bottomley A; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group and the EORTC Lung Cancer Group. Use of the lung cancer-specific Quality of Life Questionnaire EORTC QLQ-LC13 in clinical trials: A systematic review of the literature 20 years after its development. Cancer. 2015 Oct 9. doi: 10.1002/cncr.29682.

    89.  Coens C, van der Graaf WT, Blay JY, Chawla SP, Judson I, Sanfilippo R, Manson SC, Hodge RA, Marreaud S, Prins JB, Lugowska I, Litière S, Bottomley A. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Global Network Study (EORTC 62072). Cancer. 2015 Sep 1;121(17):2933-41. doi: 10.1002/cncr.29426

    90.  DiGiovanni J, Popovic M; Chow E; Cella D; Beaumont JL, Nguyen J, Chu D, Adili A, Pulenzas, N, Lechner B, Lam H, Bottomley A. Comparison of the EORTC QLQ-LC13 and the FACT-L for assessment of quality of life in patients with lung cancer. J Pain Manag. 2015 Sep;8(2):103-113.

    91.  Taphoorn MJB, Henriksson R, Bottomley A, Cloughesy T, Wick W, Mason WP, Saran F, Nishikawa R, Hilton M, Theodore-Oklota C, Ravelo A, Chinot OL. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. JCO. 2015 Jul 1;33(19):2166-75. doi: 10.1200/JCO.2014.60.3217. [Epub 2015 May 26].

    92.  Dirven L, van den Bent MJ, Bottomley A, van der Meer N, van der Holt B, Vos MJ, Walenkamp AME, Beerepoot LV, Hanse MCJ, Reijneveld JC, Otten A, de Vos FYFL, Smits M, Bromberg JEC, Taal W, Taphoorn MJB, on behalf of the Dutch Neuro-Oncology Group (LWNO). The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial. Eur J Cancer. 2015 Apr 17. pii: S0959-8049(15)00292-0. doi: 10.1016

    93.  Nguyen J, Popovic M, Chow E, Cella D, Beaumont JL, Chu D, DiGiovanni J, Lam H, Pulenzas N, Bottomley A. EORTC QLQ-BR23 and FACT-B for the assessment of quality of life in patients with breast cancer: a literature review. J Comp Eff Res. 2015 Mar;4(2):157-66. doi: 10.2217/cer.14.76

    94.  Zikos E, Coens C, Bottomley A. Health-related quality of life research in EORTC cancer clinical trials: an emphasis on quality. Belg J Med Oncol. 2015;9(1):11-15

    95.  Donneau AF, Mauer M, Coens C, Bottomley A, Albert A. Longitudinal quality of life data: a comparison of continuous and ordinal approaches. Qual Life Res. 2014 Dec;23(10):2873-81. doi: 10.1007/s11136-014-0730-8. Epub 2014 Jun 6. PMID: 24902940

    96.  Winstanley JB, Young TE, Boyle FM, Bergenmar M, Bottomley A, Burmeister B, Campana LG, Garioch JJ, King M, Nikolic DV, van de Poll-Franse LV, Saw R, Thompson JF, White EG; on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group. Cross-cultural development of a quality-of-life measure for patients with melanoma: phase 3 testing of an EORTC Melanoma Module. Melanoma Res. 2014 Oct 16. 2015 Feb;25(1):47-58. doi: 10.1097/CMR.0000000000000122

    97.  Yekaninejad MS, Pakpour AH, Tadakamadla J, Kumar S, Mosavi SH, Fridlund B, Bottomley A, Aaronson NK. Oral-health-related quality of life in patients with cancer: cultural adaptation and the psychometric testing of the Persian version of EORTC QLQ-OH17. Support Care Cancer. 2015 May;23(5):1215-24. doi: 10.1007/s00520-014-2468-9. Epub 2014 Oct 15.

    98.  Ediebah DE, Galindo-Garre F, Uitdehaag BM, Ringash J, Reijneveld JC, Dirven L, Zikos E, Coens C, van den Bent MJ, Bottomley A, Taphoorn MJ. Joint modeling of longitudinal health-related quality of life data and survival. Qual Life Res. 2015 Apr;24(4):795-804. doi: 10.1007/s11136-014-0821-6. Epub 2014 Oct 14.

    99.  Chu D, Popovic M, Chow E, Cella D, Beaumont JL, Lam H, Nguyen J, Giovanni JD, Pulenzas N, Bedard G, Bottomley A. Development, characteristics and validity of the EORTC QLQ-PR25 and the FACT-P for assessment of quality of life in prostate cancer patients. J Comp Eff Res. 2014 Sep;3(5):523-31. doi: 10.2217/cer.14.41.

 100.  Sprangers MA, Thong MS, Bartels M, Barsevick A, Ordoñana J, Shi Q, Wang XS, Klepstad P, Wierenga EA, Singh JA, Sloan JA; GeneQol Consortium. Biological pathways, candidate genes, and molecular markers associated with quality-of-life domains: an update. Qual Life Res. 2014 Sep;23(7):1997-2013. doi:10.1007/s11136-014-0656-1. Review. PubMed PMID: 24604075; PubMed Central PMCID: PMC4199387

 101.  Chow R, Lao N, Popovic M, Chow E, Cella D, Beaumont J, Lam H, Pulenzas N, Bedard G, Wong E, DeAngelis C, Bottomley A. Comparison of the EORTC QLQ-BN20 and the FACT-Br quality of life questionnaires for patients with primary brain cancers: a literature review. Support Care Cancer. 2014 Sep;22(9):2593-8. doi: 10.1007/s00520-014-2352-7. PMID: 25015058

 102.  Chiu L, Chiu N, Chow E, Cella D, Beaumont JL, Lam H, Popovic M, Bedard G, Poon M, Wong E, Zeng L, Bottomley A. Comparison of Three Shortened Questionnaires for Assessment of Quality of Life in Advanced Cancer. J Palliat Med. 2014 Aug;17(8):918-23. doi: 10.1089/jpm.2014.0012. [Epub 2014 Jun 12]

 103.  Zikos E, Ghislain I, Coens C, Ediebah DE, Sloan E, Quinten C, Koller M, Van Meerbeeck J, Flechtner H, Stupp R, Pallis A, Czimbalmos A, Sprangers M, Bottomley A. Health-Related Quality of Life in Small-Cell Lung Cancer: A Systematic Review on Reporting of Methodological and Clinical Issues in Randomized Controlled Trials. Lancet Oncol. 2014 Feb;15(2):e78-89. doi: 10.1016/S1470-2045(13)70493-5

 104.  Sodergren SC, White A, Efficace F, Sprangers M, Fitzsimmons D, Bottomley A, Johnson CD. On behalf of the EORTC Quality of Life Group. Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours. Crit Rev Oncol Hematol. 2014 Jan 17. pii: S1040-8428(14)00012-2. doi: 10.1016/j.critrevonc.2014.01.002

 105.  Bottomley A, Tridello G, Coens C, Rolland F, Tesselaar MET, Leemans CR, Hupperets P, Licitra L, Vermorken JB, Van Den Weyngaert D, Truc G, Barillot I, Lefebvre JL. An International Phase III Trial in Head and Neck Cancer: Quality of Life and Symptom Results. EORTC 24954 on Behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group. Cancer, 2014 Feb 1;120(3):390-8. doi: 10.1002/cncr.28392.

 106.  Paradowski J, Tomaszewski KA, Bereza K, Tomaszewska IM, Walocha E, Paradowska D, Skotnicki P, Greimel ER, Bottomley A. Validation of the Polish version of the EORTC QLQ-OV28 module for the assessment of health-related quality of life in women with ovarian cancer. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):157-63. doi: 10.1586/14737167.2014

 107.  Yekaninejad MS, Ahmadzadeh A, Mosavi SH, Saffari M, Pakpour AH, Tolooei F, Chow E, Bottomley A. The reliability and validity of the Iranian version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with Bone Metastases: the EORTC QLQ-BM22. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):147-56. doi: 10.1586/14737167.2014.864559.

 108.  Habets EJJ, Taphoorn MJB, Nederend S, Klein M, Delgadillo D, Hoang- Xuan K, Bottomley A, Allgeier A, Seute T, Gijtenbeek AMM, de Gans J, Enting RH, Tijssen CC, van den Bent MJ, Reijneveld JC. Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. J Neurooncol. 2014 Jan;116(1):161-8. doi: 10.1007/s11060-013-1278-0.

 109.  Quinten C, Martinelli F, Coens C, Sprangers MA, Ringash J, Gotay C, Bjordal K, Greimel E, Reeve BB, Maringwa J, Ediebah DE, Zikos E, King M, Osoba D, Taphoorn MJ, Flechtner H, Schmucker-Von Koch J, Weis J, Bottomley A. On behalf of PROBE and the EORTC Clinical Groups. A global analysis of multi-trial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. J Clin Oncol. 2014 Jan 15;120(2):302-11. doi: 10.1002/cncr.28382